Tag: Offices

The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against LOOP Industries, Inc.

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York captioned Tremblay v. Loop Industries, Inc., et al., (Case No. 1:20-cv-08538) on behalf of persons and entities that purchased or otherwise acquired Loop Industries, Inc. (“Loop” or the “Company”) (NASDAQ: LOOP) securities between September 24, 2018 and October 12, 2020, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who suffered a loss, click here to participate.

Loop is a technology company that purports to own proprietary technology that depolymerizes no- and low-waste PET plastic and polyester fiber. The resulting material is used to create PET resin for food-grade packaging.

On October 13, 2020, Hindenburg Research published a report alleging, among other things, that “Loop’s scientists, under pressure from CEO Daniel Solomita, were tacitly encouraged to lie about the results of the company’s process internally.” The report also stated that “Loop’s previous claims of breaking PET down to its base chemicals at a recovery rate of 100% were ‘technically and industrially impossible,’” according to a former employee. Moreover, the report alleged that “Executives from a division of key partner Thyssenkrupp, who Loop entered into a ‘global alliance agreement’ with in December 2018, told us their partnership is on ‘indefinite’ hold and that Loop ‘underestimated’ both costs and complexities of its process.”

On this news, the Company’s share price fell $3.78, or over 32%, to close at $7.83 per share on October 13, 2020, thereby damaging investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Loop scientists were encouraged to misrepresent the results of Loop’s purportedly proprietary process; (2) that Loop did not have the technology to break PET down to its base chemicals at a recovery rate of 100%; (3) that, as a result, the Company was unlikely to realize the purported benefits of Loop’s announced partnerships with Indorama and Thyssenkrupp; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Loop securities during the Class Period, you may move the Court no later than 60 days from the date of this notice to ask the Court to appoint you as lead plaintiff.  To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.  If you purchased Mesoblast securities, have information or would like to learn more about these claims,

Continue reading

Firm hire: Former NI Law Society president leads BLM offices | News

Insurance risk and commercial law firm BLM has appointed former president of the Law Society of Northern Ireland John Guerin as head of both the Belfast and Derry offices. 

Guerin commented: ‘Our clients’ needs are complex and have been compounded by the evolving environment in which we are all operating. I am honoured to be leading such a dedicated team that have our clients’ full confidence.’

John_Guerin

Legal expert Cormac Fitzpatrick has also been promoted to the firm’s strategy setting executive board. Fitzpatrick has overall leadership of the firm’s Irish offices working closely with the operations board, managing partner Vivienne Williams and senior partner Matthew Harrington.

The new leadership team follows the April appointments of partners Sinead Connolly and Olivia Treston as joint heads of office for Dublin.

Fitzpatrick commented: ‘As BLM and the wider law and business sectors adapt to the current challenges of the pandemic, our innovations and new leadership team position us strongly to deliver great outcomes for clients in the coming months and years.

‘Undoubtedly there have been operational challenges, however, our talented workforce has embraced our digital transformation strategy and we are confident that we will maintain momentum and our exceptional service provision across the island of Ireland in the period ahead.

BLM has seen significant business growth in its Northern Ireland office since a merger with Campbell Fitzpatrick Solicitors in 2014.

Source Article

Continue reading

The Law Offices of Frank R. Cruz Continues Its Investigation of Loop Industries, Inc. (LOOP) on Behalf of Investors

The Law Offices of Frank R. Cruz continues its investigation of Loop Industries, Inc. (“Loop” or the “Company”) (NASDAQ: LOOP) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On October 13, 2020, Hindenburg Research published a report alleging, among other things, that “[a] former Loop employee told us that Loop’s scientists, under pressure from CEO Daniel Solomita, were tacitly encouraged to lie about the results of the company’s process internally. We have obtained internal documents and photographs to support their claims.” The report also stated that “Loop’s previous claims of breaking PET down to its base chemicals at a recovery rate of 100% were ‘technically and industrially impossible,’” according to a former employee. Moreover, the report alleged that “Executives from a division of key partner Thyssenkrupp, who Loop entered into a ‘global alliance agreement’ with in December 2018, told us their partnership is on ‘indefinite’ hold and that Loop ‘underestimated’ both costs and complexities of its process.”

On this news, Loop’s stock price fell as much as 33% during intraday trading on October 13, 2020.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Loop securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013006158/en/

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

Source Article

Continue reading

Law Offices of Howard G. Smith Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors

BENSALEM, Pa.–(BUSINESS WIRE)–Oct 13, 2020–

Law Offices of Howard G. Smith announces an investigation on behalf of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX ) investors concerning the Company’s possible violations of federal securities laws.

In June 2019, the Company launched a dose-escalation Phase 1/2 clinical trial for HMI-102, its lead product candidate for the treatment of phenylketonuria. Homology “reported encouraging safety and efficacy data from the dose-escalation portion of the trial” and claimed that the data showed HMI-102 “produced a sustained reduction in phenylalanine (Phe).”

Then, on July 21, 2020, Mariner Research published a report, alleging that the Company’s comments “conveniently ignor[ed] the implications to efficacy and the business.” Citing data from a mouse study, the Phase 1/2 trial, and a key patient’s Facebook posts, the report concluded that HMI-102 “therapy is showing zero efficacy even for a high dose patient,” signifying that “the HMI-102 program is dead in the water.” Moreover, citing internal emails and analyst reports, Mariner Research claimed Homology had selectively discussed the patient’s Facebook posts with sell side analysts covering Homology and major investors.

On this news, the Company’s stock price fell $1.71 per share, or more than 10%, over three consecutive trading sessions to close at $14.77 per share on July 24, 2020, thereby injuring investors.

If you purchased Homology securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com:https://www.businesswire.com/news/home/20201013005999/en/

CONTACT: Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847

888-638-4847

howardsmith@howardsmithlaw.com

www.howardsmithlaw.com

KEYWORD: PENNSYLVANIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: LEGAL PROFESSIONAL SERVICES

SOURCE: Law Offices of Howard G. Smith

Copyright Business Wire 2020.

PUB: 10/13/2020 04:30 PM/DISC: 10/13/2020 04:31 PM

http://www.businesswire.com/news/home/20201013005999/en

Source Article

Continue reading

The Law Offices of Frank R. Cruz Announces Investigation of Loop Industries, Inc. (LOOP) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Loop Industries, Inc. (“Loop” or the “Company”) (NASDAQ: LOOP) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On October 13, 2020, Hindenburg Research published a report alleging, among other things, that “[a] former Loop employee told us that Loop’s scientists, under pressure from CEO Daniel Solomita, were tacitly encouraged to lie about the results of the company’s process internally. We have obtained internal documents and photographs to support their claims.” The report also stated that “Loop’s previous claims of breaking PET down to its base chemicals at a recovery rate of 100% were ‘technically and industrially impossible,’” according to a former employee. Moreover, the report alleged that “Executives from a division of key partner Thyssenkrupp, who Loop entered into a ‘global alliance agreement’ with in December 2018, told us their partnership is on ‘indefinite’ hold and that Loop ‘underestimated’ both costs and complexities of its process.”

On this news, Loop’s stock price fell as much as 33% during intraday trading on October 13, 2020.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Loop securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013006085/en/

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

Source Article

Continue reading

The Law Offices of Frank R. Cruz Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

In June 2019, the Company launched a dose-escalation Phase 1/2 clinical trial for HMI-102, its lead product candidate for the treatment of phenylketonuria. Homology “reported encouraging safety and efficacy data from the dose-escalation portion of the trial” and claimed that the data showed HMI-102 “produced a sustained reduction in phenylalanine (Phe).”

Then, on July 21, 2020, Mariner Research published a report, alleging that the Company’s comments “conveniently ignor[ed] the implications to efficacy and the business.” Citing data from a mouse study, the Phase 1/2 trial, and a key patient’s Facebook posts, the report concluded that HMI-102 “therapy is showing zero efficacy even for a high dose patient,” signifying that “the HMI-102 program is dead in the water.” Moreover, citing internal emails and analyst reports, Mariner Research claimed Homology had selectively discussed the patient’s Facebook posts with sell side analysts covering Homology and major investors.

On this news, the Company’s stock price fell $1.71 per share, or more than 10%, over three consecutive trading sessions to close at $14.77 per share on July 24, 2020, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Homology securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013006049/en/

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

Source Article

Continue reading

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cabot Oil & Gas Corporation (COG)

The Law Offices of Frank R. Cruz reminds investors of the upcoming October 13, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Cabot Oil & Gas Corporation (“Cabot Oil” or “the Company”) (NYSE: COG) securities between October 23, 2015 and June 12, 2020, inclusive (the “Class Period”).

If you are a shareholder who suffered a loss, click here to participate.

On July 26, 2019, the Company disclosed that it had received two proposed Consent Order and Agreements related to two Notices of Violation it had received from the Pennsylvania Department of Environmental Protection in 2017 for failure to prevent the migration of gas into fresh groundwater sources in the area surrounding Susquehanna County, Pennsylvania.

On this news, the Company’s share price fell $2.63, or over 12%, to close at $19.16 per share on July 26, 2019.

On June 15, 2020, following a grand jury investigation, the Pennsylvania attorney general’s office charged Cabot Oil with 15 criminal counts due to its failure to fix faulty gas wells, which polluted Pennsylvania’s water supplies through stray gas migration.

On this news, Cabot Oil’s stock price fell $0.67 per share, or 3.34%, to close at $19.40 per share on June 15, 2020.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Cabot had inadequate environmental controls and procedures and/or failed to properly mitigate known issues related to those controls and procedures; (2) as a result, Cabot, among other issues, failed to fix faulty gas wells, thereby polluting Pennsylvania’s water supplies through stray gas migration; (3) that the foregoing was foreseeably likely to subject Cabot to increased governmental scrutiny and enforcement, as well as increased reputational and financial harm; (4) that Cabot continually downplayed its potential civil and/or criminal liabilities with respect to such environmental matters; and (5) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased or otherwise acquired Cabot Oil securities during the Class Period, you may move the Court no later than October 13, 2020 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to

Continue reading

The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Mesoblast Limited (MESO)

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Kristal v. Mesoblast Limited, et al., (Case No. 1:20-cv-08430), on behalf of persons and entities that purchased or otherwise acquired Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) securities between April 16, 2019 and October 1, 2020, inclusive (the “Class Period”). Plaintiff pursues under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”)

If you are a shareholder who suffered a loss, click here to participate.

Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform. Its lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow. In February 2018, the Company announced that remestemcel-L met its primary endpoint in a Phase 3 trial to treat children with steroid refractory acute graft versus host disease (“aGVHD”).

In early 2020, Mesoblast completed its rolling submission of its Biologics License Application (“BLA”) with the FDA to secure marketing authorization to commercialize remestemcel-L for children with steroid refractory aGVHD.

On August 11, 2020, the FDA released briefing materials for its Oncologic Drugs Advisory Committee (“ODAC”) meeting to be held on August 13, 2020. Therein, the FDA stated that Mesoblast provided post hoc analyses of other studies “to further establish the appropriateness of 45% as the null Day-28 ORR” for its primary endpoint. The briefing materials stated that, due to design differences between these historical studies and Mesoblast’s submitted study, “it is unclear that these study results are relevant to the proposed indication.”

On this news, the Company’s share price fell $6.09, or approximately 35%, to close at $11.33 per share on August 11, 2020, on unusually heavy trading volume.

On October 1, 2020, Mesoblast disclosed that it had received a Complete Response Letter (“CRL”) from the FDA regarding its marketing application for remestemcel-L for treatment of SR-aGVHD in pediatric patients. According to the CRL, the FDA recommended that the Company “conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD.” The CRL also “identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the product’s biologic activity.”

On this news, the Company’s stock fell $6.56, or 35%, to close at $12.03 per share on October 2, 2020, on unusually heavy trading volume.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that comparative analyses between Mesoblast’s Phase 3 trial and three historical studies did not support the effectiveness of remestemcel-L for steroid refractory aGVHD due to design differences between the four studies; (2) that, as a result, the FDA was reasonably likely

Continue reading

The Law Offices of Frank R. Cruz Announces Investigation of Liberty Oilfield Services Inc. (LBRT) on Behalf of Investors

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Liberty Oilfield Services Inc. (“Liberty” or “the Company”) (NYSE: LBRT) concerning whether the board breached its fiduciary duties to shareholders.

If you are a shareholder, click here to participate.

On February 5, 2020, after the market closed, Liberty issued a press release announcing its financial and operations results for fourth quarter and full year 2019. Therein, Liberty reported full year adjusted EBITDA of $277 million, or a 37% decline over the prior year, and diluted earnings per share of $0.53, which fell significantly short of analyst forecasts.

On this news, Liberty’s stock price fell $1.07, or over 12%, to close at $7.80 per share on February 6, 2020, thereby injuring investors.

Our investigation concerns whether the Company’s board of directors breached its fiduciary duties to shareholders and/or grossly mismanaged the Company in connection with the above alleged misconduct.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you still hold Liberty shares purchased before February 5, 2020 and wish to discuss this matter with us, or have any questions concerning your rights and interests with regards to this matter, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005302/en/

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

Source Article

Continue reading

The Law Offices of Frank R. Cruz Announces Investigation of Amyris, Inc. (AMRS) on Behalf of Investors

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Amyris, Inc (“Amyris” or the “Company”) (NASDAQ: AMRS) concerning whether the board breached its fiduciary duties to shareholders.

If you are a shareholder, click here to participate.

On March 19, 2019, Amyris announced was unable to file its annual report for fiscal year ended December 31, 2018 on time due to “the significant time and resources that were devoted to the accounting for and disclosure of the significant transactions with Koninklijke DSM N.V. that closed in November 2018.” The Company also disclosed that it was “in the process of completing its evaluation of internal control over financial reporting.”

On this news, Amyris’ share price fell $0.78, or nearly 20% to close at $3.10 per share on March 20, 2019, thereby injuring investors.

Our investigation concerns whether the Company’s board of directors breached its fiduciary duties to shareholders and/or grossly mismanaged the Company in connection with the above alleged misconduct.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you still hold Amyris shares purchased before March, 2018 and wish to discuss this matter with us, or have any questions concerning your rights and interests with regards to this matter, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005290/en/

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

Source Article

Continue reading